Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 20 11 2020
accepted: 23 02 2021
pubmed: 26 2 2021
medline: 29 9 2021
entrez: 25 2 2021
Statut: ppublish

Résumé

Efferocytosis, the process through which apoptotic cells (ACs) are cleared through actin-mediated engulfment by macrophages, prevents secondary necrosis, suppresses inflammation, and promotes resolution. Impaired efferocytosis drives the formation of clinically dangerous necrotic atherosclerotic plaques, the underlying etiology of coronary artery disease (CAD). An intron of the gene encoding PHACTR1 contains rs9349379 (A>G), a common variant associated with CAD. As PHACTR1 is an actin-binding protein, we reasoned that if the rs9349379 risk allele G causes lower PHACTR1 expression in macrophages, it might link the risk allele to CAD via impaired efferocytosis. We show here that rs9349379-G/G was associated with lower levels of PHACTR1 and impaired efferocytosis in human monocyte-derived macrophages and human atherosclerotic lesional macrophages compared with rs9349379-A/A. Silencing PHACTR1 in human and mouse macrophages compromised AC engulfment, and Western diet-fed Ldlr-/- mice in which hematopoietic Phactr1 was genetically targeted showed impaired lesional efferocytosis, increased plaque necrosis, and thinner fibrous caps - all signs of vulnerable plaques in humans. Mechanistically, PHACTR1 prevented dephosphorylation of myosin light chain (MLC), which was necessary for AC engulfment. In summary, rs9349379-G lowered PHACTR1, which, by lowering phospho-MLC, compromised efferocytosis. Thus, rs9349379-G may contribute to CAD risk, at least in part, by impairing atherosclerotic lesional macrophage efferocytosis.

Identifiants

pubmed: 33630758
pii: 145275
doi: 10.1172/JCI145275
pmc: PMC8262505
doi:
pii:

Substances chimiques

Microfilament Proteins 0
Myosin Light Chains 0
PHACTR1 protein, human 0
Phactr1 protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCRR NIH HHS
ID : S10 RR027050
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL150359
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL113147
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007343
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL087123
Pays : United States
Organisme : NHLBI NIH HHS
ID : R00 HL130574
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141127
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013696
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151611
Pays : United States

Références

J Cell Sci. 2012 Dec 1;125(Pt 23):5860-72
pubmed: 22976292
Nat Rev Immunol. 2008 May;8(5):327-36
pubmed: 18421305
Immunity. 2018 Oct 16;49(4):666-677.e6
pubmed: 30291029
Cell Signal. 2012 Jan;24(1):214-23
pubmed: 21939755
N Engl J Med. 2013 May 23;368(21):2004-13
pubmed: 23697515
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1256-61
pubmed: 15831805
Circ Res. 2016 Feb 19;118(4):564-78
pubmed: 26892958
Heart. 2004 Dec;90(12):1385-91
pubmed: 15547008
J Clin Invest. 2018 Jul 2;128(7):2713-2723
pubmed: 30108191
Dev Cell. 2016 Jul 25;38(2):147-60
pubmed: 27459067
Biochem Biophys Res Commun. 2008 Apr 25;369(1):149-56
pubmed: 18155661
Nat Genet. 2013 Jan;45(1):25-33
pubmed: 23202125
Nat Genet. 2009 Mar;41(3):334-41
pubmed: 19198609
Cell Metab. 2020 Mar 3;31(3):518-533.e10
pubmed: 32004476
J Biol Chem. 2003 Nov 14;278(46):45611-9
pubmed: 12925532
Biochimie. 2015 Nov;118:151-61
pubmed: 26362351
Circ Res. 2018 Jun 8;122(12):1661-1674
pubmed: 29545365
BMC Med Genet. 2018 Jun 8;19(1):97
pubmed: 29884117
Nat Rev Immunol. 2014 Mar;14(3):166-80
pubmed: 24481336
Cell. 2017 Jul 27;170(3):522-533.e15
pubmed: 28753427
Cell. 2019 Mar 21;177(1):132-145
pubmed: 30901535
Lab Invest. 1991 Jan;64(1):5-15
pubmed: 1990208
Mol Cell Biochem. 2004 Apr;259(1-2):197-209
pubmed: 15124925
Sci Transl Med. 2015 Feb 18;7(275):275ra20
pubmed: 25695999
N Engl J Med. 2007 Aug 2;357(5):443-53
pubmed: 17634449
Clin Sci (Lond). 2020 Sep 18;134(17):2353-2368
pubmed: 32857129
PLoS One. 2012;7(6):e38663
pubmed: 22745674
Nat Genet. 2017 Jul;49(7):1113-1119
pubmed: 28530674
Circ Genom Precis Med. 2018 Oct;11(10):e002327
pubmed: 30354304
Cell. 2001 Feb 23;104(4):503-16
pubmed: 11239408
Circulation. 2007 Oct 16;116(16):1832-44
pubmed: 17938300
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1472-1479
pubmed: 25838425
Nat Genet. 2017 Sep;49(9):1385-1391
pubmed: 28714975
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
FEBS Lett. 2005 Jan 3;579(1):100-4
pubmed: 15620697
J Lipid Res. 2007 Dec;48(12):2560-70
pubmed: 17876058
Front Cardiovasc Med. 2018 Jan 08;4:86
pubmed: 29379788
Nat Genet. 2012 Jul 01;44(8):890-4
pubmed: 22751097
Nature. 2000 Sep 14;407(6801):233-41
pubmed: 11001066
Trends Cell Biol. 2020 Feb;30(2):157-167
pubmed: 31836280
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Eur Heart J. 2020 Sep 7;41(34):3239-3252
pubmed: 31972008
Nat Commun. 2020 Sep 4;11(1):4432
pubmed: 32887874
Nat Genet. 2015 Oct;47(10):1121-1130
pubmed: 26343387
Circ Res. 2018 Feb 2;122(3):433-443
pubmed: 29212778
Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1421-8
pubmed: 18451332
Nat Commun. 2016 Sep 23;7:12859
pubmed: 27659679
Circulation. 2017 Jan 31;135(5):476-489
pubmed: 28137963
J Clin Neurosci. 2020 Apr;74:265-267
pubmed: 31980275
Biochem J. 2010 Sep 1;430(2):237-44
pubmed: 20590529
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Sci Rep. 2019 Jun 18;9(1):8680
pubmed: 31213640
Circ J. 2016 Oct 25;80(11):2259-2268
pubmed: 27725526
Structure. 2012 Nov 7;20(11):1960-70
pubmed: 23041370
PLoS One. 2012;7(6):e39269
pubmed: 22723981
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830865
Mol Imaging. 2014;13:1-11
pubmed: 24622812
J Clin Invest. 2014 Mar;124(3):1083-97
pubmed: 24531546
Atherosclerosis. 2016 Jul;250:95-105
pubmed: 27187934
Nature. 2011 Aug 21;477(7363):220-4
pubmed: 21857682
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7187-92
pubmed: 15107502

Auteurs

Canan Kasikara (C)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Maaike Schilperoort (M)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Brennan Gerlach (B)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Chenyi Xue (C)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Xiaobo Wang (X)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Ze Zheng (Z)

Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

George Kuriakose (G)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Bernhard Dorweiler (B)

Department of Vascular Surgery, University of Cologne, Cologne, Germany.

Hanrui Zhang (H)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Gabrielle Fredman (G)

Department of Molecular and Cellular Physiology, Albany Medical Center, Albany, New York, USA.

Danish Saleheen (D)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Muredach P Reilly (MP)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, New York, USA.

Ira Tabas (I)

Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Department of Physiology and Cellular Biophysics and.
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH